注射用胸腺肽α1联合多索茶碱对AECOPD患者细胞免疫功能及血清炎症因子水平的影响  

Effects of Thymosinα1 for injection combined with Doxofylline on cellular immune function and serum inflammatory factors in patients with AECOPD

作　　者：贾广文 王生锋[2] 宿光明 Jia Guang-wen;Wang Sheng-feng;Su Guang-ming(Department of Critical Care Medicine,Taikang People's Hospital,Zhoukou 461400,Henan,China;Department of Critical Care Medicine,The Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Respiratory and Critical Care,Taikang People's Hospital,Zhoukou 461400,Henan,China)

机构地区：[1]太康县人民医院重症医学科,河南周口461400 [2]郑州大学第二附属医院重症医学科,河南郑州450000 [3]太康县人民医院呼吸与危重症科,河南周口461400

出　　处：《四川生理科学杂志》2025年第1期47-49,66,共4页

摘　　要：目的:探讨胸腺肽α1联合多索茶碱对慢性阻塞性肺疾病急性加重期(Acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者免疫功能、炎症因子水平的影响。方法:选取我院2021年12月至2024年1月接收的106例AECOPD患者为研究对象,依据双色球法分为对照组和联合组(n=53)分别静脉滴注多索茶碱0.3 g以及多索茶碱联合皮下注射胸腺肽α11.6 mg进行治疗。比较两组治疗2 w后临床疗效,治疗期间不良反应情况,采用肺功能仪检测两组治疗前、2 w后峰值呼气流速(Peak expiratory flow,PEF)、第1 s用力呼气容积(Forced expiratory volume in first second,FEV_(1))、用力肺活量(Forced vital capacity,FVC)、FEV_(1)/FVC水平,采用血气分析仪检测两组治疗前、2 w后氧分压(Oxygen partial pressure,PaO_(2))、二氧化碳分压(Partial pressure of carbon dioxide,PaCO_(2))水平,采用流式细胞仪检测两组治疗前、2 w后T淋巴细胞(CD4^(+)、CD8^(+)、CD3^(+))、CD4^(+)/CD8^(+)水平,采用酶联免疫法检测两组治疗前、2 w后可溶性髓样细胞触发受体(Soluble triggering receptor expressed on myeloid cell,sTREM)-1、白细胞介素(Interleukin,IL)-6、单核细胞趋化蛋白(Monocyte chemotactic protein,MCP)-1、肿瘤坏死因子(Tumor necrosis factor,TNF)-α水平。结果:联合组临床疗效96.23%高于对照组83.02%(P<0.05);治疗后联合组PEF、PaO_(2)、FEV_(1)、PaCO_(2)、FVC、FEV_(1)/FVC、sTREM-1、CD4^(+)、IL-6、CD8^(+)、CD3^(+)、TNF-α、CD4^(+)/CD8^(+)、MCP-1水平改善程度均大于对照组(P<0.05);两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论:注射用胸腺肽α1联合多索茶碱治疗能改善AECOPD患者肺功能,抑制炎症反应,增强免疫功能,安全有效。Objective:To investigate the effects of Thymosinα1 combined with Doxofylline on immune function and inflammatory factors in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A total of 106 patients with AECOPD who were admitted to our hospital from December 2021 to January 2024 were selected as the research subjects and divided into a control group and a combined group(n=53)according to the two-color ball method.They were treated with intravenous infusion of 0.3 g doxofylline and doxofylline combined with subcutaneous injection of 1.6 mg thymosinα1,respectively.The clinical efficacy of the two groups after 2 weeks of treatment was compared,as well as the adverse reactions during treatment.The levels of peak expiratory flow(PEF),forced expiratory volume in first second(FEV1),forced vital capacity(FVC),and FEV1/FVC were measured using a pulmonary function instrument before and after treatment in both groups.The levels of oxygen partial pressure(PaO_(2))and partial pressure of carbon dioxide(PaCO_(2))were measured using a blood gas analyzer before and after treatment in both groups.The levels of T lymphocytes(CD4^(+),CD8^(+),CD3^(+))and CD4^(+)/CD8^(+)were measured using a flow cytometer before and after treatment in both groups.The levels of soluble triggering receptor expressed on myeloid cell(sTREM)-1,interleukin(IL)-6,monocyte chemotactic protein(MCP)-1,and tumor necrosis factor(TNF)-αwere measured using enzyme-linked immunosorbent assay before and after treatment in both groups.Results:The clinical efficacy of the combined group was 96.23%,which was higher than that of the control group(83.02%)(P<0.05).After treatment,the improvement of PEF,PaO_(2),FEV1,PaCO_(2),FVC,FEV1/FVC,sTREM-1,CD4^(+),IL-6,CD8^(+),CD3^(+),TNF-α,CD4^(+)/CD8^(+),MCP-1 levels in the combined group were greater than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Thymosinα1 for injection combined

关 键 词：胸腺肽Α1 多索茶碱 慢性阻塞性肺疾病 免疫功能 炎症因子 

分 类 号：R563.9[医药卫生—呼吸系统]